ReviewInflammatory intestinal diseases
Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.
Review in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Eosinophilic esophagitis in children and adolescents: a clinical practice guideline.Italian journal of pediatrics · 2025Guideline
- The Relationship Between Eosinophilic Esophagitis and Laryngeal Manifestations: Pathophysiology, Clinical Overlap, and Diagnostic Challenges.Journal of clinical medicine · 2026Review
- Eosinophil diversity and function: emerging insights into subtypes and therapeutic targets.Cell death discovery · 2026Review
- Eosinophilic Esophagitis: Mechanisms of Disease and Approach to Treatment.Current allergy and asthma reports · 2026Review
- Multimodal analgesia strategies enhance postoperative recovery and mitigate inflammatory responses in women undergoing elective surgery for endometrial cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
- The Therapeutic Pipeline for Eosinophilic Esophagitis: Current Landscape and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Spatial Eosinophil Phenotypes as Immunopathogenic Determinants in Inflammatory Diseases.Cells · 2025Review
- Eosinophilic Esophagitis: Prevalence, Diagnosis, and Treatment in Childhood and Adulthood.Deutsches Arzteblatt international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eosinophilic esophagitis (EoE) is a chronic, food allergen-mediated, esophageal disease that will lead, if left untreated, to esophageal remodeling. As such, the vast majority of EoE patients need treatment. Treatment strategies include drugs, food elimination diets, and esophageal dilation. This review focuses on pharmacologic options for treatment of EoE. Summary: Orodispersible budesonide tablets (Jorveza Key Messages: Long-term effectiveness and safety data on different drugs are currently sparse. Concerted efforts of different stakeholders will be necessary to continue the endeavor of providing our patients with much-needed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.